Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor

[1]  Yu Zhao,et al.  Successful management with an effective induction regimen followed by allogeneic hematopoietic stem cell transplantation for promyelocytic blast crisis of chronic myelogenous leukemia , 2012, Annals of Hematology.

[2]  H. Kantarjian,et al.  Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. , 2008, Blood.

[3]  K. Ohyashiki,et al.  Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia. , 2010, Leukemia research.

[4]  Young-Uk Cho,et al.  Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment. , 2008, Annals of clinical and laboratory science.

[5]  P. Browett,et al.  Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia , 2007, Leukemia & lymphoma.

[6]  M. Sata,et al.  Promyelocytic Crisis of Chronic Myelogenous Leukaemia during Imatinib Mesylate Treatment , 2006, Acta Haematologica.

[7]  P. Pilot,et al.  Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib , 2006, Leukemia.

[8]  F. Guilhot,et al.  Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia , 2005, Leukemia.

[9]  Miae Lee,et al.  Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome , 2003, American journal of hematology.

[10]  L. Kjeldsen,et al.  Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8 , 2002, Leukemia.